Published in Clin Cancer Res on March 19, 2014
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res (2017) 1.40
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res (2014) 1.40
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2015) 1.30
Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst (2015) 1.29
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One (2015) 1.26
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res (2015) 1.18
Unvalidated antibodies and misleading results. Breast Cancer Res Treat (2014) 1.17
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget (2016) 1.13
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol (2015) 1.05
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res (2015) 1.05
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. J Clin Oncol (2016) 0.99
PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther (2016) 0.98
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget (2015) 0.98
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget (2015) 0.94
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology (2014) 0.93
PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology (2015) 0.93
Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Lab Invest (2014) 0.92
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One (2015) 0.90
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med (2015) 0.88
Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. J Breast Cancer (2016) 0.88
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci (2016) 0.88
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer (2016) 0.88
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget (2016) 0.87
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. PLoS One (2016) 0.87
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. Ann Surg Oncol (2015) 0.86
The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol (2016) 0.85
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer (2016) 0.85
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A (2016) 0.84
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer (2016) 0.83
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med (2016) 0.82
Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. J R Soc Interface (2015) 0.82
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med (2016) 0.81
Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) (2016) 0.80
The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. Oncoimmunology (2015) 0.80
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol (2016) 0.80
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. Sci Rep (2016) 0.79
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer (2016) 0.79
Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. Oncotarget (2016) 0.79
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget (2017) 0.79
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Front Oncol (2017) 0.79
High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget (2017) 0.78
Fully Automated RNAscope In Situ Hybridization Assays for Formalin-Fixed Paraffin-Embedded Cells and Tissues. J Cell Biochem (2016) 0.78
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus (2016) 0.78
Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol (2016) 0.78
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Int J Mol Sci (2017) 0.78
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS One (2016) 0.77
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open (2017) 0.76
Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer (2016) 0.76
Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget (2016) 0.76
Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer? Breast Cancer Res (2014) 0.76
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology (2016) 0.76
Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques. JRSM Open (2015) 0.76
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. Oncoimmunology (2015) 0.76
Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines. Int J Gynecol Cancer (2016) 0.76
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. Oncoimmunology (2016) 0.75
Predictive factors of tumor immune microenvironment for long-term follow-up in early stage breast cancer. Cancer Sci (2016) 0.75
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care (Basel) (2016) 0.75
Recent advances in understanding antitumor immunity. F1000Res (2016) 0.75
Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Sci (2017) 0.75
Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. Onco Targets Ther (2017) 0.75
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. J Breast Cancer (2016) 0.75
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Med Sci Monit (2017) 0.75
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncoimmunology (2016) 0.75
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget (2017) 0.75
Immunotherapy for Breast Cancer: What Are We Missing? Clin Cancer Res (2017) 0.75
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res (2016) 0.75
Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine Growth Factor Rev (2016) 0.75
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology (2017) 0.75
Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. J Gastric Cancer (2016) 0.75
Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues. Pancreas (2016) 0.75
PD-L1 and intratumoral immune response in breast cancer. Oncotarget (2017) 0.75
Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. Breast Cancer (Auckl) (2017) 0.75
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci Rep (2017) 0.75
Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget (2017) 0.75
PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget (2017) 0.75
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75
Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB. Oncotarget (2017) 0.75
PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget (2017) 0.75
DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. J Clin Invest (2017) 0.75
Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget (2017) 0.75
Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. Oncotarget (2017) 0.75
Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer. J Cancer (2017) 0.75
Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget (2017) 0.75